CASI Pharmaceuticals (FRA:ENM) Total Stockholders Equity : €14.23 Mil (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is CASI Pharmaceuticals Total Stockholders Equity?

CASI Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €14.23 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. CASI Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 was €1.06. The ratio of a company's debt over equity can be used to measure how leveraged this company is. CASI Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 was 1.20.

CASI Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for CASI Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Total Stockholders Equity Chart

CASI Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

65.70

67.03

74.78

42.08

22.16

CASI Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															36.97	29.75	26.98	22.16	14.23

CASI Pharmaceuticals (FRA:ENM) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

CASI Pharmaceuticals's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(14.23	-	0)	/	13.4014
	=	1.06

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

CASI Pharmaceuticals's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	17.099)	/	14.23
	=	1.20

CASI Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CASI Pharmaceuticals (FRA:ENM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (FRA:ENM) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

CASI:USA

Address

9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850

Website

https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.

CASI Pharmaceuticals (FRA:ENM) Headlines

No Headlines